Biotech Stocks New Highs: Fate Therapeutics (NASDAQ:FATE), Synthetic Biologics (NYSEMKT:SYN), Celladon Corp (NASDAQ:CLDN), Kindred Biosciences (NASDAQ:KIN)

Fate Therapeutics, Inc. (NASDAQ:FATE) announced that it has enrolled the first patient in its phase II study (PUMA − P rohema in UM bilical cord blood transplant in A dults) on Prohema. Fate Therapeutics Inc. (NASDAQ:FATE) stock performance was 27.14% in last session and finished the day at $11.15. Traded volume was 295,227.00 shares in the last session and the average volume of the stock … Continue reading Biotech Stocks New Highs: Fate Therapeutics (NASDAQ:FATE), Synthetic Biologics (NYSEMKT:SYN), Celladon Corp (NASDAQ:CLDN), Kindred Biosciences (NASDAQ:KIN)

Biotech Stocks Touching New Highs: Relypsa Inc. (NASDAQ:RLYP), Vanda Pharmaceuticals (NASDAQ:VNDA), OHR Pharmaceutical (NASDAQ:OHRP), Xencor (NASDAQ:XNCR)

Relypsa, Inc. (NASDAQ:RLYP) is a pharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. Relypsa Inc. (NASDAQ:RLYP) stock performance was 2.66% in last session and finished the day at $43.62. Traded volume was 126,739.00 shares in the last session and the average volume of the stock remained 113,686.00 shares. Relypsa … Continue reading Biotech Stocks Touching New Highs: Relypsa Inc. (NASDAQ:RLYP), Vanda Pharmaceuticals (NASDAQ:VNDA), OHR Pharmaceutical (NASDAQ:OHRP), Xencor (NASDAQ:XNCR)

Tesaro Inc. (NASDAQ:TSRO) announced Thursday morning that it has entered into an exclusive, worldwide license agreement and immuno-oncology antibody collaboration with AnaptysBio Inc. TESARO Inc. (NASDAQ:TSRO) stock performance was -5.40% in last session and finished the day at $36.76. Traded volume was 732,104.00 shares in the last session and the average volume of the stock remained 469,070.00 shares. TESARO Inc. (NASDAQ:TSRO) insider ownership is 21.88%. … Continue reading Biotech Top Losers: TESARO Inc. (NASDAQ:TSRO), Dyax Corp. (NASDAQ:DYAX), Regulus Therapeutics (NASDAQ:RGLS), Cara Therapeutics (NASDAQ:CARA)

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) on Feb. 25 reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was 8.79% in last session and finished the day at $8.17. Traded volume was 18.32 million shares in the last session and the average volume of the stock remained 16.55 million … Continue reading Biotech Top Gainer: Ariad Pharmaceuticals (NASDAQ:ARIA), CEL-SCI Corporation (NYSEMKT:CVM), Synthetic Biologics (NYSEMKT:SYN), Agenus Inc. (NASDAQ:AGEN)

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release fourth quarter and full year 2013 financial results after market close on Wednesday, March 19, 2014. Xencor Inc. (NASDAQ:XNCR) stock performance was -1.58% in last session and finished the day at $13.68. Traded volume was 99,904.00 shares … Continue reading Biotech Overbought Socks: Xencor Inc. (NASDAQ:XNCR), Albany Molecular Research (NASDAQ:AMRI), Oncothyreon (NASDAQ:ONTY), OXiGENE Inc. (NASDAQ:OXGN)

A US federal court yesterday invalidated Pfizer Inc.’s (NYSE:PFE) key patent covering its anti-inflammatory pill Celebrex. The patent, which was set to lapse in December 2015, would have given Pfizer an 18-month extension from the expiry of the patent for the major ingredient in the drug, celecoxib. Pfizer Inc. (NYSE:PFE) stock performance was -2.69% in last session and finished the day at $31.12. Traded volume … Continue reading Biotech Active Stocks: Pfizer Inc. (NYSE:PFE), Geron Corporation (NASDAQ:GERN), Cell Therapeutics (NASDAQ:CTIC), Chelsea Therapeutics International (NASDAQ:CHTP)